Combined effects of vasopressin V2 receptor antagonist and loop diuretic in humans

Clinical Nephrology

Volumn 59, Issue 3, 2003, Pages 164-173

  Shimizu, K ^a  

^a Sumiyoshi Clinic Hospital   (Japan)

Author keywords

Edema; Free water excretion; Furosemide; Hyponatremia; OPC 31260

Indexed keywords

ELECTROLYTE; FUROSEMIDE; LOOP DIURETIC AGENT; MOZAVAPTAN; PLACEBO; SODIUM ION; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR; WATER;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; EDEMA; FREE WATER CLEARANCE; HENLE LOOP; HUMAN; HUMAN EXPERIMENT; HYPONATREMIA; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SERUM OSMOLARITY; SODIUM BLOOD LEVEL; SODIUM EXCRETION; URINE VOLUME; VOLUNTEER; WATER TRANSPORT;

EID: 0037345624     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP59164     Document Type: Article

References (34)

1. Bartoli E, Satta A, Faedda R, Olmeo NA, Soggia G, Branca G 1983 A furosemide test in the functional evaluation of the human nephron in vivo. J Clin Pharmacol 23: 56-64
2. Berl T, Robertson GL 2000 Pathophysiology of water metabolism. In: Brenner BM (ed) The Kidney (6th edn). WB Saunders, Philadelphia, pp 866-924
3. Brooks DP, Koster PF, Albrightson-Winslow CR, Stassen FL, Huffman WF, Kinter LB 1988 SK&F 105494 is a potent antidiuretic hormone antagonist in the rhesus monkey (Macaca mulatta). J Pharmacol Exp Ther 245: 211-215
4. Claria J, Jiménez W, Arroyo V, Guarner F, López C, Villa G, Asbert M, Rivera F, Rodés J 1989 Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology 97: 1294-1299
5. De Fronzo RA, Smith JD 1995 Disorders of potassium metabolism, hyperkalemia. In: Arieff Al, De Fronzo RA (eds) Fluid Electrolyte and Acid-Base Disorders. Churchill Livingstone, New York, pp 319-386
6. De Lima J, Caillens H, Beaufils M, Ardaillou R 1981 Effect of furosemide-induced plasma volume reduction on plasma antidiuretic hormone in normal and hypertensive subjects. Clin Nephrol 115: 246-251
7. De Fronzo RA, Arieff AL 1995 Disorders of sodium metabolism, hyponatremia. In: Arieff AL, Defronzo RA (eds) Fluid, Electrolyte and Acid-Base Disorders. Churchill Livingstone, New York, pp 255-303
8. Decaux G 2001 Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 110: 582-584
9. Dubb J, Allison N, Tatoian D, Blumberg A, Lee K, Stote R 1987 SK&F 101926 is antiduretic in man (abstract). Kidney Int 31: 267
10. Freeman RH, Davis JO 1983 Factors controlling renin secretion and metabolism. In: Genest J, Kuehel O, Hamet P, Cantin M (eds) Hypertension. McGraw-Hill, New York, pp 225-250
11. Greger RF 1996 Loop diuretics. In: Greger R, Knauf H, Mutschler E (eds) Handbook of Experimental Pharmacology, Diuretics. Springer, Heidelberg, pp 221-274
12. Gross PA, Pehrisch H, Rascher W, Schöming A, Hackenthal E, Ritz E 1987 Pathogenesis of clinical hyponatremia. Observations of vasopressin and fluid intake in 100 hyponatremic medical patients. Eur J Clin Invest 17: 123-129
13. - cotransport family. Kidney Int 49: 1638-1641
14. 2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 292: 288-294
15. Jamison RL, Buerkert J, Lacy F 1971 A micropuncture study of collecting tubule function in rats with hereditary diabetes insipidus. J Clin Invest 50: 2444-2452
16. Jonassen TEN, Christensen S, Kwon T-H, Langhoff S, Salling N, Nielsen S 2000 Renal water handling in rats with decompensated liver cirrhosis. Am J Physiol Ren Physiol 279: F1101-F1109
17. Jonassen TEN, Nielsen S, Christensen S, Petersen S 1998 Decreased vasopressin-mediated renal water reabsorption in rats with compensated liver cirrhosis. Am J Physiol Ren Physiol 275: F216-F225
18. 2 receptor antagonism decreases urinary aquaporin-2 excretion in patients with c hronic heart failure. J Am Soc Nephrol 10: 2165-2170
19. Masilamani S, Knepper MA, Burg MB 2000 Urine concentration and dilution. In: Brenner BM (ed) The Kidney (6th edn). WB Saunders, Philadelphia, pp 595-635
20. Nielsen S, Terris J, Andersen D, Ecelbarger C, Frøkiaer J, Jonassen T, Marples D, Knepper MA, Peterson JS 1997 Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct. Proc Natl Acad Sci USA 94: 5450-5455
21. 2 receptor antagonist on the development of heart failure in rats. J Cardiovasc Pharmacol 27: 275-282
22. Ohnishi A, Orita Y, Okahara R, Fujihara H, Inoue T, Yamamura Y, Yabuuchi Y, Tanaka T 1993 Potent aquaretic agent, a novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest 92: 2653-2659
23. Reeves WB, Andreoli TE 2000 Sodium chloride transport in the loop of Henle, distal convoluted tubule, and collecting duct. In: Seldin DW, Giebisch G (eds): The Kidney, Physiology and Pathophysiology, (3rd ed), Lippincott Williams and Wilkins, Philadelphia, pp 1333-1369
24. Robertson GL, Athar S 1976 The interaction of blood osmolality and blood volume in regulating plasma vasopressin in man. J Clin Endocrinol Metab 42: 613-620
25. Saito T, Ishikawa S, Abe K, Kamoi K, Yamada K, Shimizu K, Saruta T, Yoshida S 1997 Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 82: 1054-1057
26. Schrier RW 1988 Pathogenesis of sodium and water retention in high-output and low-out-put cardiac failure, nep hrotic syndrome, cirrhosis, and pregnancy. N Engl J Med 319: 1065-1072, 1127-1134
27. Schwartz J, Reid IA 1981 Effect of vasopressin blockade on blood pressure regulation during hemorrhage in conscious dogs. Endocrinology 109: 1778-1780
28. Shimizu K, Hoshino M 1978 Application of vasopressin radioimmunoassay to clinical study: role of vasopressin in hypo- and hypernatremia and some other disorders of water metabolism. Contrib Nephrol 9: 42-60
29. Shimizu K, Nakano S, Nakano Y, Ando M, Seki K, Kameda N 1991 Ectopic atrial natriuretic peptide production in small cell lung cancer with the syndrome of inappropriate antidiuretic hormone secretion. Cancer 68: 2284-2288
30. 2 antagonist OPC-31260 in hydropenic humans. Kidney Int 48: 220-226
31. Shimizu K, Kurosawa K, Sanjo T, Hoshino M, Nonaka T 2002 Solute-free versus electrolyte-free water clearance in the analysis of osmoregulation. Nephron 91: 51-57
32. Tsuboi Y, Ishikawa S, Fujisawa G, Okada K, Saito T 1994 Therapeutic efficacy of the nonpeptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int 46: 237-244
33. 2 vasopression receptor antagonist, in patients with advanced heart failure. Circulation 104: 2417-2423
34. 2 receptor antagonist. Br J Pharmacol 105: 787-791